PAREXEL International (France)

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Eric Van Cutsem, Fernando Rivera, Scott Berry et al. · Annals of Oncology · 2009 · 534 citations

Medicine, Oncology, Pharmacotherapy +10

A Novel Inhibitor That Suspends the Induced Fit Mechanism of UDP-N-acetylglucosamine Enolpyruvyl Transferase (MurA)

Susanne Eschenburg, Melanie A. Priestman, Farid Abdul-Latif et al. · Journal of Biological Chemistry · 2005 · 64 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +14

Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)

Karissa Johnston, Adrian R. Levy, Paul Lorigan et al. · European Journal of Cancer · 2012 · 44 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

Meletios Α. Dimopoulos, Meral Beksaç, Lotfi Benboubker et al. · Haematologica · 2013 · 39 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study)

Célèste Lebbé, Paul Lorigan, Paolo A. Ascierto et al. · European Journal of Cancer · 2012 · 28 citations · Full text

Medicine, Oncology, Surgery +15